Indicative listing context
Abridge Stock Price (Pre-IPO)
Ask for the Abridge stock price and the honest answer is that none exists officially, since the healthcare AI company remains private and unlisted. In place of a market quote, Segmara maintains an indicative pre-IPO reference mark for Abridge, shown above with the date it was set, compiled from private-market signals across healthcare AI. Abridge is offered through a direct structure, and a free email tracker lets you follow the mark before any listing happens. The catalogue also lines Abridge up against other healthcare AI companies for comparison.
Indicative private-market reference marks: not a quote and not an offer. Segmara does not sell, broker, or arrange share purchases.
SEGMARA PRO
Filing alerts for Abridge
Segmara Pro: a weekly IPO brief plus SEC filing alerts for 60+ companies, including Abridge, from automated EDGAR checks every weekday, posted in the members forum; 7-day free trial, then $15 a month (plus any applicable tax). Research only, no share sales.
When will Abridge IPO? · Free Abridge tracker · Read a free issue · See the IPO calendar
Private-share data lens
Public round-by-round marks are incomplete for this company. Segmara shows the listing mark and keeps the seed-to-IPO analysis focused on verifiable funding, tender, or secondary signals.
| Stage | Date | Valuation / price signal | Why it matters |
|---|---|---|---|
| Seed / early | Private | Not reliably public | Do not invent a seed price when the source set is thin. |
| Growth rounds | Private | Company and market sources vary | Use public sources and official company releases. |
| Segmara listing | Current | $186.49/unit · as of September 4, 2026 | Indicative reference only, not a quote or an offer. |
| IPO status | Current | No public ticker shown here | Watch official company releases and the free Segmara IPO calendar. |
Seed-to-IPO path
Illustrative completeness map. Longer bars mean stronger public data or more useful current pricing context, not lower risk.
Regulation D filings on record
The SEC full-text index lists 2 Form D filings for Abridge AI Inc. (CIK 1737537), the filer behind Abridge. The most recent was filed 2025-06-30 and reports $315,934,583 sold of a $318,998,519 offering.
| Filed | Amount sold | Offering size | First sale | Source |
|---|---|---|---|---|
| 2025-06-30 | $315,934,583 | $318,998,519 | 2025-06-12 | SEC filing |
| 2024-03-08 | $141,103,188 | $149,999,730 | 2024-02-22 | SEC filing |
A Form D reports an exempt offering under Regulation D: what the issuer told the SEC it raised, not a valuation and not a per-share price.
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
| Metric | Value | Context |
|---|---|---|
| Canonical route | /abridge-stock-price | Stable URL path for AI and search extraction. |
| Article title | Abridge Stock Price (Pre-IPO) | Main page topic. |
| Attached public sources | 4 | Number of citation links rendered at the bottom of the article. |
| Segmara listed companies | 51 | Live private-company listings in the public catalogue. |
| Priced listings | 37 | Catalogue listings with visible indicative or direct marks. |
| Listings without an indicative price | 14 | Catalogue listings where a public price is intentionally not invented. |
| Company | Abridge | Named company covered by this page. |
| Symbol label | ABRG | Segmara display symbol; not a public stock ticker unless separately stated. |
| Sector | Healthcare AI | Catalogue sector used for comparison and internal linking. |
| Listing structure | Secondary | How the listing is categorized on Segmara. |
| Segmara mark | $186.49/unit · as of September 4, 2026 | Visible listing mark, or no indicative price yet. |
| Sector peer count | 1 | Number of live Segmara listings in Healthcare AI. |
| Structure peer count | 26 | Number of live Segmara listings categorized as Secondary. |
| Price rank | 14 of 37 | Ranked highest-to-lowest among Segmara listings with visible marks. |
| Price percentile | 65th | Percentile among visible Segmara catalogue marks. |
| Catalogue median mark | $92.58 | Median visible mark across priced Segmara listings. |
| Premium/discount to median | +101% | Difference between this listing mark and the catalogue median mark. |
Data fingerprint chart
| Stage | Timing | Price / valuation signal | Interpretation |
|---|---|---|---|
| Formation | Private | Early ownership | The first value creation happens before ordinary public-market access. |
| Growth rounds | Private | Institutional repricing | Later rounds and tenders create the price history buyers study. |
| Segmara listing | Current | $186.49/unit · as of September 4, 2026 | Indicative reference only, not a quote or an offer. |
| Exit path | Future | IPO, tender, acquisition, or continued private status | Liquidity timing remains company-specific. |
| Chart metric | Score | Interpretation |
|---|---|---|
| Listing price percentile | 65 / 100 | $186.49/unit · as of September 4, 2026 ranks 14 of 37 priced listings |
Analytical lens
Search intent
Searches like 'Abridge Stock Price (Pre-IPO)' are research questions: what a filing or a company statement confirms, what has only been reported, and what is still unknown.
What counts as a listing step
For an IPO, the primary record is a registration statement filed with the securities regulator of the listing market, such as an S-1 or F-1 on SEC EDGAR for a US listing. Funding rounds, valuations and secondary-market prices are context, not listing steps.
Segmara role
Segmara is an independent research site. It does not sell, broker, or arrange share purchases, and nothing on this page is investment advice.
How a company reaches a US listing
The SEC filing trail
DraftThe company can first submit a draft registration statement (DRS) for confidential SEC review.
S-1 or F-1The registration statement goes public on SEC EDGAR: Form S-1, or Form F-1 for many foreign companies. A company that used a draft must file publicly at least 15 days before its roadshow.
AmendmentsS-1/A or F-1/A amendments answer SEC comments, and one of them adds the expected price range.
PricingOnce the SEC declares the registration effective, the company sets the price with its underwriters and files the final prospectus, usually a 424B4.
First tradeThe shares start trading on the exchange named in the prospectus, such as Nasdaq or the NYSE.
Sources: SEC, March 3, 2025 · Investor.gov, October 14, 2022 · Regulation S-K Item 501 · SEC Form F-1.
Abridge on SEC EDGAR
Segmara Pro checks SEC EDGAR for Abridge filings every weekday and posts an alert in the members forum when one of these public filings appears. You can also check yourself with EDGAR full-text search.
Key takeaways
- Live indicative mark for Abridge renders in the data summary below.
- Compare Abridge with other healthcare AI names in the catalogue.
- Track the indicative price free by email. No card, no documents, no brokerage account.
Risk notes
- Private-company exposure can be illiquid, transfer-restricted, and hard to value.
- Indicative marks and reported valuations are orientation points, not executable quotes.
- Availability of any route can depend on jurisdiction, eligibility, structure, and approval.
Public source links
Related reviews
Questions
Can I buy shares through Segmara?
No. Segmara is an independent research site. Segmara does not sell, broker, or arrange share purchases.
What can I do on Segmara?
Read the research pages, follow indicative marks with the free tracker (email only), check the free IPO calendar, or subscribe to Segmara Pro for a weekly IPO brief.
Is Segmara affiliated with the named company or platform?
No. Segmara is not affiliated with Abridge or any named issuer, affiliate, investor, underwriter, or platform referenced on this page.
What is Abridge's stock price today?
Abridge is private, so there is no official public stock price. Segmara publishes an indicative pre-IPO reference mark in the data summary on this page. It is not a live exchange quote and not an offer to sell.
Is Abridge publicly traded?
No. Abridge has not held an IPO and its shares do not trade on any public exchange. Any price shown for Abridge is an indicative private-market estimate.
How can I get exposure to Abridge?
Segmara does not sell, broker, or arrange share purchases. You can follow the indicative mark for Abridge with the free email tracker.
What is Abridge worth?
Segmara does not state a fixed valuation for Abridge. The indicative mark in the data summary below reflects private-market signals, and reported valuations elsewhere are orientation points, not executable quotes.
Next step
Track Abridge free.
Get the indicative Abridge price by email. Free, email only. No card, no documents, no brokerage account.
Get the free Abridge tracker